Daily intelligence on the peptide research industry.

Research Pipeline

Epitalon: Mechanism, Evidence Base, and Regulatory Position After the July 2026 PCAC Vote

Epitalon is a synthetic tetrapeptide developed over four decades of Russian research and centred on proposed telomerase activation and pineal-gland regulation. Following the PCAC's 7-to-4 vote in its favour on 24 July 2026, it now sits closer to legitimate US compounding than at any previous point — though formal 503A listing remains months of rulemaking away. This profile examines what the evidence actually shows and what the regulatory path forward means for UK research procurement.

13 Aug 2026

Research Pipeline

Thymosin Alpha-1: The 28-Amino-Acid Immunomodulator With Decades of Clinical Data — Mechanism, Evidence, and Regulatory Position in 2026

Thymosin alpha-1 (Tα1) carries one of the deepest clinical records of any peptide in active research — more than 11,000 human subjects, approval in roughly 35 countries, and a long-running debate over its status in the United States and United Kingdom. This briefing examines its mechanism, what the evidence base actually supports as of 2026, and where the compound sits within the ongoing US reclassification process.

12 Aug 2026

Research Pipeline

CagriSema: The GLP-1 and Amylin Combination With an FDA Decision Expected Before Year-End

Novo Nordisk's CagriSema — a fixed-dose combination of semaglutide 2.4 mg and the long-acting amylin analogue cagrilintide — is now under FDA review for obesity, with a decision anticipated in Q4 2026. This briefing sets out the mechanism, the pivotal REDEFINE trial results, the REDEFINE-4 head-to-head complication, and what the compound's regulatory pathway means for UK research-procurement teams.

09 Aug 2026

Research Pipeline

BPC-157: What the Evidence Base Actually Shows — Mechanism, Human Data, and Post-PCAC Regulatory Position

BPC-157 is among the most discussed peptides in regenerative research, yet its human clinical evidence remains critically thin. Following the FDA PCAC's narrow 8-6 recommendation in July 2026, this spotlight examines what the peer-reviewed literature actually shows, what the rulemaking timeline means for procurement, and what UK research professionals need to understand about its current legal status.

08 Aug 2026

Research Pipeline

Retatrutide's TRIUMPH Programme: Five Positive Phase 3 Readouts, a BLA Confirmed for Q1 2027 — What the Data Mean for Research Procurement

Eli Lilly has completed five positive Phase 3 studies for retatrutide, its first-in-class GIP/GLP-1/glucagon triple agonist, with topline TRIUMPH-2 and TRIUMPH-3 results released on 23 July 2026. The company has confirmed a Biologics Licence Application to the FDA in Q1 2027, marking the clearest regulatory timeline yet for the most efficacious agent in the GLP-1 class. For research procurement teams, the data package now available reframes how this investigational peptide should be sourced…

07 Aug 2026

Research Pipeline

Epitalon: The Pineal Tetrapeptide With Four Decades of Longevity Research — and a Fresh PCAC Recommendation

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from bovine pineal gland extract, studied for over 40 years for telomerase activation, melatonin regulation, and geroprotection. On 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee recommended it for inclusion on the 503A Bulks List — a significant regulatory milestone that places the compound closer to US clinical access than at any previous point, while substantive evidentiary gaps remain.

02 Aug 2026

Research Pipeline

Thymosin Alpha-1: The Immunomodulatory Peptide With Decades of Clinical Data — and a Complicated Regulatory Position

Thymosin alpha-1 (Tα1) has been approved as Zadaxin in more than 35 countries for chronic hepatitis B and studied across over 80 clinical trials — making it one of the most clinically documented peptides available. Yet it remains unapproved in the US and carries no MHRA marketing authorisation in the UK, leaving research-procurement teams navigating a jurisdiction-dependent patchwork of access and legal constraints.

01 Aug 2026

Research Pipeline

CJC-1295 and Ipamorelin: The GHRH/GHRP Combination That Sits Outside the PCAC Process — What the Evidence Shows

While the FDA's Pharmacy Compounding Advisory Committee dominated peptide headlines this week, CJC-1295 and Ipamorelin occupy a distinct regulatory position: neither compound was among the twelve peptides removed from Category 2 in April 2026, nor is either scheduled for PCAC review. This briefing examines their mechanisms, the state of the clinical evidence, and what their current status means for UK research procurement.

29 Jul 2026

Research Pipeline

Semax: The Russian Neuropeptide That Just Won an FDA Compounding Recommendation — What the Evidence Actually Shows

Semax, a synthetic heptapeptide derived from the ACTH(4-10) sequence, received a non-binding PCAC recommendation for inclusion on the FDA's 503A Bulk Drug Substances List on 24 July 2026. This profile examines its mechanism, the depth of its evidence base, and what the rulemaking path ahead means for research procurement.

28 Jul 2026

Research Pipeline

MOTS-c: The Mitochondria-Encoded Peptide With a Decade of Preclinical Evidence and a Critical FDA Compounding Vote Eleven Days Away

MOTS-c, a 16-amino acid peptide encoded within mitochondrial DNA, is set for formal FDA advisory review on 23 July 2026 as part of the PCAC's evaluation of seven peptides for the 503A Bulk Drug Substances List. FDA briefing documents propose that it should not be listed, citing insufficient human data and characterisation gaps — yet a Phase 2a trial in prediabetes is now registered, adding new urgency to procurement decisions for UK research labs.

25 Jul 2026

Research Pipeline

KPV: The Alpha-MSH Tripeptide With Two Decades of Preclinical Evidence and an FDA Compounding Vote Nine Days Away

KPV (Lys-Pro-Val) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with a substantive body of preclinical evidence in inflammatory bowel disease, wound healing, and dermatology. On 23 July 2026, it faces its first formal FDA scientific review at the Pharmacy Compounding Advisory Committee — and the agency's own briefing documents lean against listing it on the 503A Bulk Drug Substances List.

25 Jul 2026

Research Pipeline

Thymosin Alpha-1: The Thymic Peptide With Four Decades of Clinical Evidence and a Divided Global Regulatory Map

Thymosin alpha-1 (Tα1) occupies a singular position in the peptide landscape: it is approved as a prescription medicine in more than 35 countries under the brand name Zadaxin, yet it holds no FDA approval in the United States and no MHRA marketing authorisation in the UK. This briefing reviews the compound's mechanism, the depth of its clinical evidence base, its evolving US compounding status, and what the regulatory asymmetry means for UK research-procurement professionals.

25 Jul 2026